Pressemitteilungen zu dem Thema neurological


Unterkategorien

PresseMitteilungen zu dem Schlagwort neurological


Dimension Craft, Inc., Didgebridge LLC Delivers Digital Product Catalog to Mizuho America Inc. at CNS Annual Meeting 2017

Dimension Craft, Inc. and Didgebridge LLC delivered a custom digital product catalog as part of Mizuho America’s exhibit presentation at this year’s CNS (Congress of Neurological Surgeons) Annual Meeting. Dimension Craft , Inc. and Didgebridge, LLC have a strategic partnership to combine the strengths of both firms to best serve their clients’ interests and marketing requirements. Dimension Craft, Inc. is an integrated exhibit designer and builder with decades of client experience and Didgebrid ...


04.11.2017

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facili ...


01.11.2017

Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

LOS ANGELES, CA -- (Marketwired) -- 10/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced additional positive preclinical efficacy results for the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, wh ...


19.10.2017

Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 10/16/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.The publication of the international patent filing is the fi ...


16.10.2017

Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough

LOS ANGELES, CA -- (Marketwired) -- 10/04/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the achievement of a biosynthesis breakthrough.Vitality has developed a proprietary biosynthesis technology that can modify cannabinoids in o ...


04.10.2017

Vitality Biopharma Receives Updated SeeThruEquity Price Target of $2.40

LOS ANGELES, CA -- (Marketwired) -- 09/27/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, ...


27.09.2017

Vitality Biopharma to Present at The MoneyShow San Francisco Conference

LOS ANGELES, CA -- (Marketwired) -- 08/23/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to provide a presentation and participate in a cannabis industry panel session at the MoneyShow San Francisco investment conference.Company CEO Ro ...


23.08.2017

Vitality Biopharma Closes $1 Million Private Placement

LOS ANGELES, CA -- (Marketwired) -- 08/02/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1 million private placement.As previously described on the Company''s Current ...


02.08.2017

Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, know ...


19.07.2017

Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

LOS ANGELES, CA -- (Marketwired) -- 06/21/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, announced today that Company Advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montréal, Canada.Dr. Ryz will provide a po ...


21.06.2017

Vitality Biopharma to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA -- (Marketwired) -- 05/30/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 7th Annual LD Micro Invitational in Los Angeles.The corporate presentation is on Tuesday, June 6th at 9:00 ...


30.05.2017

Vitality Biopharma Announces Positive Results for Cannabinoid Antibiotics

LOS ANGELES, CA -- (Marketwired) -- 05/10/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatme ...


10.05.2017

Vitality Biopharma Adds Key Clinical Advisors in Gastroenterology

LOS ANGELES, CA -- (Marketwired) -- 05/03/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce and welcomes the appointments of Dr. Douglas A. Drossman and Dr. Mark Gerich as clinical advisors with expertise in gastroenterology a ...


03.05.2017

Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

LOS ANGELES, CA -- (Marketwired) -- 04/20/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the release of one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory ...


20.04.2017

Vitality Biopharma Appoints Pharma Industry Veteran to Advance Cannabosides Regulatory Development

LOS ANGELES, CA -- (Marketwired) -- 04/12/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the appointment of Tracy Rockney, J.D., Co-Founder & Chief Operating Officer, OneSource Regulatory, to the position of Senior Regulatory Advisor.Tracy Rockney, J.D. was f ...


12.04.2017

Vitality Biopharma Announces International Patent Filing for Neural Repair Treatments

LOS ANGELES, CA -- (Marketwired) -- 04/05/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international patent application in March 2017 that describes compounds discovered to be effective in a drug screening model of neural repair.The underlying ...


05.04.2017

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

LOS ANGELES, CA -- (Marketwired) -- 03/02/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the main psychoactive chemical found in cannabis or marijuana, which enable targ ...


02.03.2017

Vitality Biopharma to Present at SeeThruEquity 3rd Annual Innovations Investor Conference in Miami

LOS ANGELES, CA -- (Marketwired) -- 02/16/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise there will be a corporate presentation at the SeeThruEquity 3rd Annual Innovations Investor Conference to be held on Wednesday, February ...


16.02.2017

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

LOS ANGELES, CA -- (Marketwired) -- 02/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production of cannabinoid glyc ...


01.02.2017

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA -- (Marketwired) -- 01/09/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.Company CE ...


09.01.2017

Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies

LOS ANGELES, CA -- (Marketwired) -- 10/19/16 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced results of recent drug formulation studies that documented substantial modifications to key physiochemical properties of cannabinoids through ...


19.10.2016

Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications

LOS ANGELES, CA -- (Marketwired) -- 09/13/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a written by Robert Brooke, Company CEO, sheds new light on key factors in the fight against the increasing epidemic of prescription painkiller related deaths.In his ...


13.09.2016

Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

LOS ANGELES, CA -- (Marketwired) -- 09/12/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Pa ...


12.09.2016

Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio

LOS ANGELES, CA -- (Marketwired) -- 08/24/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced a significant expansion of its glycoside prodrug intellectual property portfolio through the filing of U.S. patent application 62/363,808, which expands upon two previous pat ...


24.08.2016

Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO"

LOS ANGELES, CA -- (Marketwired) -- 08/17/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that effective immediately, its common stock now trades on the over-the-counter market under the symbol "VBIO."Trading of the company''s stock und ...


17.08.2016

Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/27/16 -- (OTCQB: STVFD) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease.Vitality Biopharma has developed a new cl ...


27.07.2016

Vitality Biopharma to Present at LD Micro and BIO Conferences

LOS ANGELES, CA -- (Marketwired) -- 06/01/16 -- Vitality Biopharma, Inc. (OTCQB: STVF), a company dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Company CEO Mr. Robert Brooke will be presenting and meeting with investors at the upcoming 2016 LD Micro Invitational and BIO International Conference in June.Vitality Biopharma to present on Tuesd ...


01.06.2016

Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development

LOS ANGELES, CA -- (Marketwired) -- 05/09/16 -- (OTCQB: STVF) (the "Company") is pleased to announce that it is changing its name to Vitality Biopharma, Inc. and that the Company will be dedicated to development of cannabinoid prodrug pharmaceuticals, and unlocking the power of cannabinoids for treatment of serious neurological and inflammatory disorders.In a recent shareholder letter available on the new corporate website at: , the Company''s CEO, Robert Brooke, stated, &q ...


09.05.2016

Landmark Report Could Help Canadians Affected by Brain Conditions Remain Employed Says Leading Brain Health Coalition

TORONTO, ONTARIO -- (Marketwired) -- 09/04/15 -- Neurological Health Charities Canada (NHCC) applauds the findings in a landmark report by the Institute for Research on Public Policy (IRPP) including the call for a new and collaborative approach to Canada''s income, disability and employment support systems."Every day, far too many Canadians living with brain diseases, disorders and injuries and their caregivers have the double dilemma of having to deal with a major health probl ...


04.09.2015

Inside the Brain Waves of the Fantasy Football Fanatic

TORONTO, ON -- (Marketwired) -- 02/04/15 -- Global media agency MEC, , and Brainsights, a Toronto-based consumer research and strategy firm, today released findings from a neurological study which recorded and evaluated the bio-metric brain wave activity of 30 adults (Male and Females, ages 21-55) to measure levels of engagement with a range of content.While Super Bowl XLIX has come to a close, the football season is not over in the minds of fans, specifically the Fantasy Football fan. Accordin ...


04.02.2015

Change-Maker Award Winners to be Honoured at BrainWave 2013

TORONTO, ONTARIO -- (Marketwired) -- 07/25/13 -- ATTN: Assignment editors and health reporters -Neurological Health Charities Canada (NHCC) has announced the winners of its "Change-Maker Award," honouring two passionate advocates for brain health in Canada.The Change-Maker Award recognizes an individual and an organization that has made a meaningful difference in improving the quality of life for Canadians living with brain conditions. The recipients this year are Jim Mann, and the On ...


25.07.2013

Florida Lays Out Wilkommen Mat for $188 Million Max Planck Florida Institute, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwire) -- 12/19/12 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Florida was excited to watch a dream turn into reality with the opening of the $188 million Max Planck Florida in Jupiter. Originally reported in 2007, it was a big win for the Sunshine State when the esteemed Max Plank Society (Munich, Germany) chose Jupiter as the site for its first operation outside of Europe. The Max Planck Society was founded more than 60 years ago i ...


19.12.2012

Passaic Sleep Medicine & Neurological Services Expands to Bergen County

RUTHERFORD, NJ -- (Marketwire) -- 08/31/12 -- today announced their latest partner practice, , led by who is board-certified in neurology, sleep medicine, and clinical neurophysiology.Dr. Fawad Mian specializes in the assessment and treatment of neurological disorders, as well as the diagnosis and treatment of many sleep disorders. He began his burgeoning practice in 2011 where he regularly sees patients with a variety of complaints including back and neck pain, headaches, tremors, numbness/ti ...


31.08.2012

The NIH Urges Bystanders to Recognize the Signs of Stroke and Call 9-1-1 Immediately

BETHESDA, MD -- (Marketwire) -- 05/10/12 -- May is National Stroke Awareness Month. is urging the public to know the symptoms of stroke and to call 9-1-1 if they witness someone having a stroke.is the fourth leading cause of death in the United States and the leading cause of adult disability. Someone suffers a stroke every 40 seconds in the United States, with a stroke-related death occurring every 4 minutes. Stroke is often more common and more deadly, with incidence and mortality rates sig ...


10.05.2012

SRS Commitment to Physician Productivity Drives EHR Purchase Decision for 17 Providers at Culicchia Neurological Clinic

MONTVALE, NJ -- (Marketwire) -- 04/10/12 -- , the leader in productivity-enhancing for high-performance physicians, today announced that Culicchia Neurological Clinic has selected the and SRS Patient Portal for its 17 providers and 3 locations. Culicchia Neurological Clinic has 3 offices in the New Orleans, Louisiana, area and provides high-quality neurological care to patients in the region."Other EHR vendors told us unabashedly that we would have to decrease our patient load by 50 per ...


10.04.2012



All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 76


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.